Refractory Marginal Zone Lymphoma Clinical Trials

5 recruitingLast updated: June 18, 2026

There are 5 actively recruiting refractory marginal zone lymphoma clinical trials across 19 countries. Studies span Phase 3, Phase 1, Phase 2, Phase 4. Top locations include Hangzhou, Zhejiang, China, Antwerp, Belgium, Argenteuil, Île-de-France Region, France. Updated daily from ClinicalTrials.gov.


Refractory Marginal Zone Lymphoma Trials at a Glance

5 actively recruiting trials for refractory marginal zone lymphoma are listed on ClinicalTrialsFinder across 6 cities in 19 countries. The largest study group is Phase 3 with 2 trials, with the heaviest enrollment activity in Hangzhou, Antwerp, and Argenteuil. Lead sponsors running refractory marginal zone lymphoma studies include Beijing InnoCare Pharma Tech Co., Ltd., Fred Hutchinson Cancer Center, and Lixia Sheng.

Browse refractory marginal zone lymphoma trials by phase

Treatments under study

About Refractory Marginal Zone Lymphoma Clinical Trials

Looking for clinical trials for Refractory Marginal Zone Lymphoma? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Refractory Marginal Zone Lymphoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Refractory Marginal Zone Lymphoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 15 of 5 trials

Recruiting
Phase 2

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaHodgkin Lymphoma+16 more
Fred Hutchinson Cancer Center60 enrolled1 locationNCT04195633
Recruiting
Phase 3

A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma

Relapsed/Refractory Follicular LymphomaRelapsed/Refractory Marginal Zone Lymphoma (R/R MZL)
Regeneron Pharmaceuticals470 enrolled169 locationsNCT06149286
Recruiting
Phase 1

B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies

Recurrent Chronic Lymphocytic LeukemiaRecurrent Follicular LymphomaRecurrent Small Lymphocytic Lymphoma+12 more
Mayo Clinic27 enrolled1 locationNCT06191887
Recruiting
Phase 3

Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma

Relapsed/Refractory Marginal Zone Lymphoma
Beijing InnoCare Pharma Tech Co., Ltd.324 enrolled19 locationsNCT06082102
Recruiting
Phase 4

Clinical Study of OR for Second-line Treatment of Refractory MZL

OR Regimen for Relapsed/Refractory Marginal Zone Lymphoma
Lixia Sheng39 enrolled3 locationsNCT06134284